Scandinavian Candesartan Acute Stroke Trial (SCAST)


Phase 3 Results N/A

Summary of Purpose

The purpose of this trial is to assess whether the blood pressure lowering agent candesartan (an angiotensin receptor type 1 blocker) is effective when given to patients with acute stroke and elevated blood pressure. Hypothesis: AT1 receptor blockade with candesartan in acute stroke will: 1. reduce the risk of death or major disability at 6 months by a 6% absolute risk reduction, relative...

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 30 June 2011.

1 Jun 2005 6 Jul 2005 1 Sep 2010 1 Sep 2010 1 Sep 2006 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
  • Purpose: Treatment
  • Endpoint: Efficacy Study
  • Intervention: Parallel Assignment


Not available